Výsledky vyhledávání - "Ruth E. Feltell"

Supplementary Methods, Figure Legends 1-7 from AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

PDF file - 81K, Supplementary data comprising the materials and methods for (i) crystallography (ii) gene expression studies (iii) siRNA studies and Supplementary Figure legends 1-7

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::136ef480c6dff64c10335140171ee9da
https://doi.org/10.1158/1078-0432.22446023.v1

Zobrazit plný text záznamu

Supplementary Table 5B from AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

XLS file - 703K, Gene expression data for CCT128930: Genes that showed at least a 1.5 Fold Change in at least one treated sample compared to vehicle control and were differentially expressed between the treatment groups (Welch ANOVA FDR5%)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::264e5ae7347bb9dfece9541b75115729
https://doi.org/10.1158/1078-0432.22446017.v1

Zobrazit plný text záznamu

Data from AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Purpose: Deregulated phosphatidylinositol 3-kinase pathway signaling through AGC kinases including AKT, p70S6 kinase, PKA, SGK and Rho kinase is a key driver of multiple cancers. The simultaneous inhibition of multiple AGC kinases may increase antitu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73dad559501b49bb682286db9d7d443d
https://doi.org/10.1158/1078-0432.c.6520622

Zobrazit plný text záznamu

Data from Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

Autor: Neil T. Thompson, John F. Lyons, David M. Cross, Donna-Michelle Smith, E. Jonathan Lewis, Nicola G. Wallis, Ruth E. Feltell, Matthew S. Squires

Cyclin-dependent kinases (CDK), and their regulatory cyclin partners, play a central role in eukaryotic cell growth, division, and death. This key role in cell cycle progression, as well as their deregulation in several human cancers, makes them attr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6803f777c0bd846db8bcf543842eac89
https://doi.org/10.1158/1535-7163.c.6531420.v1

Zobrazit plný text záznamu

Supplementary Data from Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

Autor: Neil T. Thompson, John F. Lyons, David M. Cross, Donna-Michelle Smith, E. Jonathan Lewis, Nicola G. Wallis, Ruth E. Feltell, Matthew S. Squires

Supplementary Data from Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7296b69e6a265a700d44ee128a55941b
https://doi.org/10.1158/1535-7163.22484466

Zobrazit plný text záznamu

Supplementary Table 6C from AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

XLS file - 66K, Genes that showed at least a 1.5 Fold Change in at least one treated sample compared to vehicle control and were differentially expressed between the treatment groups (Welch ANOVA FDR5%) for both CCT128930 and AT13148

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02505457843f17ab3c7bd679c87ef577
https://doi.org/10.1158/1078-0432.22446008

Zobrazit plný text záznamu

Supplementary Data for M S Squires et al from Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

Autor: Neil T. Thompson, John F. Lyons, David M. Cross, Donna-Michelle Smith, E. Jonathan Lewis, Nicola G. Wallis, Ruth E. Feltell, Matthew S. Squires

Additional information to provide an insight into the full kinase selectivity profile of AT7519 and full details of its pharmakokinetic parameters

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::427461d2f3a707d2ebe36ee1f0b1e296
https://doi.org/10.1158/1535-7163.22484469

Zobrazit plný text záznamu

Supplementary Figures 1-7, Tables 1-4 from AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

PDF file - 553K, Supplementary Figure 1. Phosphorylation of AKT substrates remains suppressed, despite pSer473 AKT induction. Supplementary Figure 2. The pharmacokinetic-pharmacodynamic profile and antitumor activity of AT13148 in PTEN-deficient PC3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66309a130e6558ca6307e2e123bca36e
https://doi.org/10.1158/1078-0432.22446026

Zobrazit plný text záznamu

Akademický článek

Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.

Publikováno v: Journal of Medicinal Chemistry; Jul2008, Vol. 51 Issue 16, p4986-4999, 14p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání